/ /

  • linkedin
  • Increase Font
  • Sharebar

    Ranibizumab provides solid safety, efficacy in real-world population

    Data at 1 and 2 years follow-up indicated expected relative preservation of visual acuity


    The visual acuity outcomes at 12 months in treatment-naïve patients with AMD showed that about 5.6 injections were administered and 8.7 at 24 months with respective letter scores of 3.4 and 2.0, the same trend as in the previously treated patients.

    In patients with DME and the vein occlusions, at 12 months the visual acuities were good and at 24 months the same small loss of letters was seen.

    Ocular serious adverse events developed in very few patients, 0.54% at 12 months and 0.7% at 24 months. The rates of non-ocular events were 6.52% and 13.34%, respectively, at the two time points.

    “The patients in the LUMINOUS Study had more diverse demographics than in the pivotal trials and were more representative of the real world,” Dr. Mitchell summarized. “The 1- and 2-year follow-up data indicated the expected relative preservation of visual acuity.”

    Country-level and subanalyses will provide further insights. No new safety signals were identified.

    “The LUMINOUS Study will provide an invaluable source of long-term real-world data,” Dr. Mitchell concluded.


    Paul Mitchell, MD

    E: [email protected]

    This article was adapted from Dr. Mitchell’s presentation during Retina Subspecialty Day at the 2014 meeting of the American Academy of Ophthalmology. Dr. Mitchell is a consultant for Novartis, which sponsored the LUMINOUS Study.


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results